Abstract. Purpose: In a study to determin the effectiveness of ionizing radiation on the deterioration of visual acuity (VA) due to choroidal neovascularisation (CNV) the affected eyes of l0 patients were treated with a total dose of 24 Gy (6 Gy fractions). A special lenssparing technique was used to avoid cataract development. During 30 months of follow-up the visual acuity (VA) and scar size (SS) of the treated eyes and fellow eyes of all 10 patients were evaluated. Results: After 30 months of follow-up 5 eyes showed a stable VA and fluorescein angiogram (FA) appearance. Concerning 4 out of 5 eyes with progressive disease, the 4 eyes treated with radiation therapy had better VA and smaller SS as compared with the untreated fellow eyes with exudative AMD. Conclusions: The results suggest that 24 Gy either stabilizes or delays the deleterious effects of CNV on the visual acuity. Until now no late side effects have been observed.
Introduction
The exudative form of age-related macular degeneration (AMD), with the development of choroidal neovascularisation (CNV), is a leading cause of blindness in western countries. The effect of laser photocoagulation for selected cases of subfoveal CNV is well known from the macular photocoagulation study (MPS) investigations [1] [2] [3] [4] . The patient must accept an immediate and permanent decrease of VA after laser photocoagulation, but will have better VA using low-vision aids [1] [2] [3] . Only in case of a small CNV with a moderate or poor VA foveal ablation is recommended [4] .
Other modalities of laserphotocoagulation including foveal sparing techniques are being proposed as alternative treatments but their definitive value has not been proved [5] . Only a few patients with recent subfoveal CNV are suitable for laser therapy, because a large proportion (87%) of patients have an occult type of CNV at presentation [6] . Alternative forms of therapy for CNV are proposed, like submacular surgery, Interferon therapy, ICG-guided laser therapy and Thalidomide therapy but none of these new therapies seems to be valuable [7] .
Patients with unilateral age-related exudative maculopathy developed neovascular membranes in the fellow eye in 31% of cases after 4 years of followup, and in general patients with exudative disease in one eye develop CNV in the fellow eye at a rate of about 10% per year [8] . The hypothesis that ionizing radiation may prevent endothelial cell proliferation and/or induce aberrant vessel obliteration and influences macrophages depended growth factors and/or regulatory genes, in case of CNV, is under investigation [7] .
After the first report concerning the effect of radiation therapy on subfoveal CNV in 1992, several other reports were published [9] [10] [11] [12] [13] [14] . We are now able to present the results after 30 months of follow-up concerning ten patients treated with radiation therapy with a total dose of 24 Gy (6 Gy fractions).
We decided to do a longer follow-up in this group of patients because initially they showed the best results after 12 months post-irradiation in our pilot study [11, 13] .
Materials and methods
This study was performed with permission of the institutional ethical committee for clinical experiments. The early results of this group of patients were previously published [11, 13] . Ten patients with subfoveal CNV and recent decrease of VA were treated with a total dose of 24 Gy in 4 fractions of 6 Gy in the macular area. The time between two consecutive fractions was 1 week and the overall treatment time was 3 weeks. The dose was delivered by two 1 square cm 16 MV photon beams. The two photon beams diverge 30 degree from the eye axis and cross the eye axis in the macular area. By this technique the lens will receive less than 20% of the dose.
All patients underwent a complete ophthalmic examination of both eyes, including FA, before treatment and 3, 12, 18 and 30 months post-treatment. The early, mid and late venous phase of the pre-and post-treatment angiograms were analysed using an over-projection sheet for measuring the size of the membrane (in disc diameters = DD) and the leakage of fluorescein in the late phase. When there was an increase in size of the CNV in the early phase and/or an increase in late phase leakage the CNV membrane was considered to be progressive. When no change between the pre-and post-treatment angiograms was seen, the CNV was considered as stable. Any CNV with a classic component but partial occult (including subretinal bloud and/or fluid or late undetermined leakage) was classified as occult type of CNV.
A decrease in VA was defined as a drop of 2 or more lines at the Snellen test. A stable VA was defined as an increase or decrease within 2 lines from initial best corrected VA. After 30 months of follow-up the VA and FA of the treated eyes and fellow eyes of all 10 patients were documented.
Results
The patients treated with a total dose of 24 Gy (6 Gy fractions) showed the following characteristics (Tables 1 and 2 
Conclusions
Thirty months after radiotherapy, with a total dose of 24 Gy, 5 out of 10 patients have a stable VA without progression of the CNV on FA (Table 1) . Patient 1, 5, 9 and 10 presented with a classic CNV, while patient 2 had an occult CNV. The VA initially was better than 0.1 and remained stable in all cases at 30 months after radiotherapy. The other 5 patients had progressive disease with a decrease in VA and an increase in SS despite radiation therapy (Table 2) . Patient 3, 6 and 7 ended up with a VA of finger counting at 1 or 2 meter, while patient 4 and 6 had a VA of 0.1 and 0.08 respectively after 30 months. did not see any severe side-effects of this radiation therapy such as radiation retinopathy or dry eyes. Slight changes in lensopacification, however, can not be ruled out.
Discussion
In exudative AMD new capillaries proliferate under the retinal pigment epithelium and/or between the retinal pigment epithelium and the retina after they have broken through Bruch's membrane. They leak blood, lipoproteins and subretinal fluid in the active phase. Over a period of months fibrous tissue appaers with the development of a fibrovascular disciform scar, with secondary destruction of the overlying photoreceptors and the remaining retinal pigment epithelium. According to Bird there are no well formulated concepts conceming the mechanism by which neovascularisation is induced. Maybe macrophages cause vasoproliferation by producing growth factors [15] . Finger et al. concluded after reviewing the literature that possibly radiotherapy indirectly effect genes resulting in growth arrest and / or apoptosis [14] . The Belfast study group postulated that radiotherapy acts to minimise size and intensity of the disciform response, through arresting the proliferation Figure 5B . Late phase of the FA. Late phase of the FA of the untreated left eye with disciform scarring and a stable SS of 6 DD after 30 months of follow-up. There is clearly a difference in scar size between the treated right eye ( Figure 4C ) of patient 4 and the untreated left eye ( Figure 5B ). Although the patient had slight myopic correction in both eyes (S-2.0), she also had age-related peripapillary atrophy.
of endothelial cells resulting in mitotic cell death and through its attenuating effects on the inflammatory response resulting in a reduced disciform scar [12] . Their results concerning radiotherapy for exudative AMD are encouraging, because the VA was significantly better and the SS was smaller in 11 eyes treated with radiotherapy, compared with the untreated fellow eyes with disciform scarring after a mean follow-up of 28 months [12] .
After reviewing the literature they concluded that concordance in scar size between the eyes of untreated patients was found to be highest when the duration of the disease was at least 12 months in the second eye to be affected. This implies that the appearance of the fibrovascular disciform scar does not change substantially after 12 months from initial presentation [12] .
The natural course of the visual acuity in patients with classic or occult CNV is known from many studies [1] [2] [3] [4] . The VA of eyes with untreated subfoveal CNrV with an initial VA of 0.1 or better, will decrease to 0.08 or worse in 44% of eyes after 3 months of follow-up and in 80.5% of eyes after 24 months of follow-up.
When compared to the natural course of the disease (80.5% of eyes deteriorate to a VA of 0.08 or worse within 24 months) radiation therapy with a dose of 24 Gy seems to have a beneficial effect on the VA (3 of 10 eyes had a VA of 0.08 or worse within 30 months ).
Although 5 eyes showed progresssive disease after radiation therapy, we noticed in 4 of them a better VA and smaller SS after 30 months, when compared with the untreated fellow eyes with exudative AMD. These results confirm the results of the Belfast study group [12] .
Radiation may have some negative side effects on the eye when doses are given beyond tolerance levels. The lens is a relatively radiosensitive structure and opacification will develop when doses exceed 6 -12 Gy.
In this study the radiation was applied in such a way that the lens was more or less spared. Until now there are no indications that there is an increased incidence of cataract in the treated eyes. More severe side effects such as radiation retinopathy or radiation optic neuropathy are rare after doses of 46.5 Gy and 55 Gy (2.0 Gy fractions) respectively [16] . Four fractions of 6 Gy, given in 3 weeks, is more or less biologically equivalent to 50 Gy given in 25 daily fractions of 2 Gy. The incidence of radiation damage after 24 Gy (6 Gy fractions) is expected to be very low and quite safe [16, 17] . As expected no cases of radiation retinopathy are observed until now.
In conclusion, after a substantial period of follow-up (30 months), 7 of 10 patients treated with a total dose of 24 Gy (6 Gy fractions) in the macular area, maintained a VA of 0.08 or better while, concerning the natural course data, 20% was expected.
This data, including the reduction in scar area after radiation treatment, suggest a beneficial effect of radiation therapy in subfoveal exudative agerelated disease.
The overall conclusion during the meeting of the American Academy of Ophthalmology in October 1995 was that there is a strong theoretical basis for this therapy but that a definite answer has to come from long-term prospective randomized controlled trials. In several centers over the world, including in the Netherlands, these trials are under way.
